Novuspharma SpA Announces Financial Results for the Six Months Ended 30 June 2003
August 07, 2003 12:00 ET
|
Novuspharma SpA
MILAN, Italy, August 7, 2003 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the six months ended 30 June...
Novuspharma SpA -- Novuspharma's Pixantrone Regimen Produces High Response Rates In Relapsed Aggressive Lymphoma
July 07, 2003 02:05 ET
|
Novuspharma SpA
BRESSO, Italy, July 7, 2003 (PRIMEZONE) -- Novuspharma SpA (Other OTC:NVUSF) (Nuovo Mercato: NOV.MI and NOV IM), a biopharmaceutical company focused on developing new cancer therapeutics, today...
Novuspharma SpA Announces Financial Results for the Twelve Months ended December 31, 2002
February 28, 2003 12:30 ET
|
Novuspharma SpA
MONZA, Italy, February 28, 2003 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the twelve months ended...
Novuspharma SpA Announces Financial Results for the Nine Months Ended September 30, 2002
November 13, 2002 14:18 ET
|
Novuspharma SpA
BRESSO, Italy, Nov. 13, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato: NOV.MI), a biopharmaceutical company focused on cancer, today announces financial results for the nine months ended 30...
Novuspharma SpA Announces Financial Results for the First Quarter Ended March 31, 2002
May 15, 2002 04:55 ET
|
Novuspharma SpA
BRESSO, Italy, May 15, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato: NOV.MI) (ISIN:IT0001482444), a biotechnology company focused on cancer, today announced financial results for the first...
Novuspharma Acquires Rights to Anti-Angiogenesis Research Program from Prolifix
May 15, 2002 04:01 ET
|
Novuspharma SpA
BRESSO, Milan and OXFORD, U.K., May 15, 2002 (PRIMEZONE) -- Novuspharma SpA (Nuovo Mercato:NOV.MI) (ISIN: IT0001482444) today announced that it has acquired full rights to the anti-angiogenic...